Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5884205 | 0.87 | MCHR1 (1.00) | MCHR1NCF1 | |
| SCHEMBL5884456 | 0.85 | MCHR1 (1.00) | MCHR1NCF1 | |
| SCHEMBL5884656 | 0.84 | MCHR1 (0.82) | MCHR1NCF1 | |
| SCHEMBL5883752 | 0.84 | MCHR1 (1.00) | MCHR1NCF1 | |
| SCHEMBL5884086 | 0.83 | MCHR1 (1.00) | MCHR1NCF1 | |
| SCHEMBL7259257 | 0.83 | MCHR1 (1.00) | MCHR1NCF1 | |
| SCHEMBL20873729 | 0.83 | MCHR1 (0.54) | MCHR1NCF1 | |
| SCHEMBL5884109 | 0.83 | MCHR1 (0.85) | MCHR1NCF1 | |
| SCHEMBL5884570 | 0.82 | MCHR1 (0.76) | MCHR1NCF1 | |
| SCHEMBL5884531 | 0.82 | MCHR1 (1.00) | MCHR1NCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6989392-B2 | 2-Aminoquinolines as melanin concentrating hormone receptor antagonists | ABBOTT LABORATORIES (US) | 2006-01-24 | — | — | US | claimed |
| US-20040063756-A1 | 2-Aminoquinolines as melanin concentrating hormone receptor antagonists | ABBVIE INC. | 2004-04-01 | — | — | US | claimed |
| WO-2003105850-A1 | 2-AMINOQUINOLINES AS MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 2003-12-24 | — | — | WO | claimed |
| US-11767301-B2 | Bi-functional molecules to degrade circulating proteins | YALE UNIVERSITY (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | UNIV YALE (US) | 2023-07-27 | — | — | US | disclosed |
| US-20210145974-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | YALE UNIVERSITY | 2021-05-20 | — | — | US | disclosed |
| US-20210139436-A1 | Bi-functional Molecules to Degrade Circulating Proteins | YALE UNIVERSITY | 2021-05-13 | — | — | US | disclosed |
| US-6989392-B2 | 2-Aminoquinolines as melanin concentrating hormone receptor antagonists | ABBOTT LABORATORIES (US) | 2006-01-24 | — | — | US | disclosed |
| US-20040063756-A1 | 2-Aminoquinolines as melanin concentrating hormone receptor antagonists | ABBVIE INC. | 2004-04-01 | — | — | US | disclosed |
| WO-2003105850-A1 | 2-AMINOQUINOLINES AS MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 2003-12-24 | — | — | WO | disclosed |
| US-4006127-A | Cationic diazacyanine dyestuffs | BAYER AKTIENGESELLSCHAFT (DT) | 1977-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767301-B2 | Bi-functional molecules to degrade circulating proteins | MIF, ASGR1, FCGR2A | MCHR1 680/4885NCF1 654/4885 |
| US-20040063756-A1 | 2-Aminoquinolines as melanin concentrating hormone receptor antagonists | MCHR1, MCHR2, MC1R | MCHR1 1/4885NCF1 3219/4885 |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | ASGR1, LDLR, FCGR2A | MCHR1 976/4885NCF1 1501/4885 |
| US-20210145974-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | ASGR1, LDLR, FCGR3B | MCHR1 761/4885NCF1 1700/4885 |
| US-20210139436-A1 | Bi-functional Molecules to Degrade Circulating Proteins | MIF, ASGR1, FCGR2A | MCHR1 680/4885NCF1 654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.